Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aerie Pharmaceuticals (AERI)

Aerie Pharmaceuticals (AERI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”)....

ALC : 74.80 (-0.17%)
AERI : 15.25 (+0.07%)
ImmunoGen (IMGN) Q3 Loss Wider, Sales Beat, '22 View Up

ImmunoGen (IMGN) reports a wider-than-expected loss in third-quarter 2022. Nevertheless, it beat revenue estimates. The company raises its financial guidance for 2022

NVS : 89.49 (-0.39%)
LLY : 342.10 (-1.70%)
IMGN : 4.75 (+0.85%)
AERI : 15.25 (+0.07%)
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates

Aerie (AERI) delivered earnings and revenue surprises of 35.71% and 2.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AERI : 15.25 (+0.07%)
SAGE : 43.37 (-3.56%)
Aerie: Q3 Earnings Snapshot

Aerie: Q3 Earnings Snapshot

AERI : 15.25 (+0.07%)
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results...

AERI : 15.25 (+0.07%)
Zoetis' (ZTS) Lags Q3 Earnings Estimates, Lowers 2022 Guidance

Zoetis' (ZTS) earnings miss estimates in third-quarter 2022. Revenues, though up, also miss estimates due to the supply constraints in the international market. Zoetis lowers its financial guidance.

NBIX : 108.25 (-0.12%)
ZTS : 165.18 (-1.82%)
AERI : 15.25 (+0.07%)
ASRT : 4.01 (-2.67%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBTX, POSH, PBFX, RNWK, AERI

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SBTX : 5.87 (+1.03%)
POSH : 17.90 (unch)
PBFX : 19.90 (-2.40%)
RNWK : 0.7300 (+0.03%)
AERI : 15.25 (+0.07%)
The Zacks Analyst Blog Highlights SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals

SilverBow Resources, Amalgamated Financial, PHX Minerals, Richardson Electronics and Aerie Pharmaceuticals are part of The Zacks top Analyst Blog.

RELL : 23.14 (+0.04%)
AERI : 15.25 (+0.07%)
SBOW : 26.68 (-0.30%)
PHX : 3.81 (-1.30%)
AMAL : 22.60 (-5.28%)
Talaris (TALS) Down on Patient Death From Renal Transplant Study

Talaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its experimental drug, FCR001, in living donor kidney transplant patients. Stock down.

CPRX : 15.52 (-2.94%)
AERI : 15.25 (+0.07%)
ACER : 2.36 (-2.48%)
TALS : 1.3400 (-2.19%)
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains

Here are four top-ranked liquid stocks, Oxford Industries (OXM), Aerie Pharmaceuticals (AERI), Perion Network (PERI), and Pure Storage (PSTG), which investors can add to their portfolio for returns.

OXM : 117.23 (+2.46%)
PERI : 33.23 (+3.17%)
AERI : 15.25 (+0.07%)
PSTG : 28.30 (+0.21%)

Barchart Exclusives

Is Corn Ready for a Seasonal February Rally?
After correcting a portion of the recent rally off the seasonal lows, corn appears to be ready to resume its post-harvest rally, as February has historically seen the uptrend continue into the first week of March. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar